Financings in Brief: Cardiometrics
This article was originally published in The Gray Sheet
Cardiometrics: Files registration statement with the Securities and Exchange Commission for an initial public offering of 2.2 mil. shares of its common stock. Mountain View, California-based Cardiometrics has developed the FloWire Doppler guidewire and the FloMap ultrasound instrument, both intravascular devices used "to measure blood flow impairment caused by coronary artery disease." The firm says that it anticipates its shares to be sold for between $10 and $12 each. Dillon, Read & Co. will serve as lead managers for the offering, which is expected to occur in late October or early November. Needham & Co. will co-manage...
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.